편두통 역학 분석과 예측(2026년)

The Global Migraine population is estimated to grow from 99.61 million patients in 2026 at a CAGR of 0.8% to 106.68 million patients in 2035.

The global migraine epidemiology landscape highlights migraine as one of the most prevalent and disabling neurological disorders worldwide, representing a significant public health challenge and a major contributor to healthcare utilization and productivity loss. Epidemiology analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic trends, disease severity, gender distribution, age-specific prevalence, regional epidemiology, and future disease burden. Growing awareness of neurological disorders, improved diagnostic practices, and expanding access to healthcare services continue to enhance migraine recognition and patient management across developed and emerging markets.

Migraine is a chronic neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia. According to recent Global Burden of Disease (GBD) estimates, migraine affected approximately 1.16-1.20 billion people globally in 2021, representing a global prevalence of approximately 14-15%. Migraine remains one of the leading causes of years lived with disability (YLDs), particularly among individuals between 15 and 49 years of age, and is substantially more common among women than men.

The epidemiology of migraine is influenced by genetic susceptibility, hormonal factors, environmental triggers, lifestyle changes, stress, sleep disturbances, obesity, and psychiatric comorbidities such as anxiety and depression. Increasing urbanization, sedentary lifestyles, changing work environments, excessive screen exposure, and rising mental health disorders continue contributing to the growing burden of migraine worldwide. Although prevalence rates have remained relatively stable over recent decades, the absolute number of affected individuals continues to increase due to population growth and aging.

Advances in digital health technologies, artificial intelligence-assisted diagnostics, wearable monitoring devices, electronic headache diaries, and telemedicine are improving disease detection, patient monitoring, and long-term management. Healthcare systems are increasingly recognizing migraine as a chronic neurological disorder requiring comprehensive care, resulting in greater emphasis on early diagnosis, preventive treatment, and personalized management strategies. As awareness and access to specialized headache care continue improving, the diagnosed and treated patient population is expected to increase steadily throughout the forecast period.

Market Drivers

Rising Global Disease Burden

• Migraine remains one of the most common neurological disorders worldwide and a leading cause of disability among working-age adults.
• Growing disease awareness and improved healthcare access continue supporting higher diagnosis rates and earlier intervention.

Increasing Awareness and Early Diagnosis

• Public health initiatives, patient education programs, and improved physician awareness are encouraging earlier diagnosis and more effective disease management.
• Earlier identification supports improved treatment outcomes and long-term patient care.

Expansion of Neurology Services

• Healthcare systems continue investing in specialized headache clinics, neurological care centers, and telemedicine services.
• Improved access to neurologists and headache specialists is strengthening disease diagnosis and treatment.

Advances in Diagnostic Technologies

• Digital headache diaries, wearable monitoring devices, mobile health applications, and artificial intelligence-assisted clinical decision support are improving disease identification and long-term epidemiological tracking.
• These technologies support more accurate diagnosis and personalized patient management.

Growing Healthcare Investment

• Increasing healthcare expenditure and expanded insurance coverage for neurological disorders continue strengthening migraine diagnosis and treatment worldwide.

Market Restraints

Underdiagnosis and Undertreatment

• A significant proportion of migraine patients remain undiagnosed or inadequately treated because symptoms are frequently underestimated or mistaken for other headache disorders.
• Delayed diagnosis may increase disease burden and reduce quality of life.

Variability in Clinical Presentation

• Migraine presents with considerable variation in symptoms, attack frequency, and severity among patients.
• Clinical heterogeneity may complicate diagnosis and epidemiological assessment.

Limited Access to Specialist Care

• Many low- and middle-income countries continue facing shortages of neurologists, headache specialists, and dedicated headache clinics.
• Healthcare disparities continue affecting diagnosis and long-term disease management.

Epidemiology Insights

By Disease Type

• The migraine population includes individuals with episodic migraine, chronic migraine, migraine with aura, migraine without aura, vestibular migraine, and medication-overuse headache associated with chronic migraine.
• Episodic migraine accounts for the largest proportion of diagnosed cases, while chronic migraine contributes disproportionately to disability and healthcare utilization.

By Age Group

• Migraine affects individuals of all ages but is most prevalent among adolescents and adults between 15 and 49 years, representing one of the leading causes of disability in this economically productive population.
• Disease burden may decline with advancing age but remains clinically significant among older adults.

By Gender

• Women experience migraine at substantially higher rates than men, largely because of hormonal influences and reproductive factors.
• Female predominance remains consistent across most global epidemiological studies.

By Diagnosis Status

• The epidemiological population includes diagnosed patients receiving acute or preventive therapies, newly diagnosed individuals, and a considerable number of undiagnosed or untreated patients requiring improved healthcare access and specialist evaluation.

Regional Insights

• North America represents one of the largest diagnosed migraine populations owing to advanced healthcare infrastructure, widespread neurological care, high disease awareness, and strong adoption of preventive therapies. Comprehensive insurance coverage and expanding use of digital health technologies continue supporting improved diagnosis and disease management.
• Europe maintains a substantial migraine patient population supported by well-established healthcare systems, specialized headache centers, and increasing investment in neurological research. Germany, the United Kingdom, France, Italy, and Spain continue reporting significant disease burden while expanding access to preventive care and innovative migraine therapies.
• Asia Pacific is expected to witness the fastest growth in diagnosed migraine cases during the forecast period due to expanding healthcare infrastructure, increasing awareness of neurological disorders, improving access to specialist care, and rising healthcare expenditure across China, Japan, India, South Korea, and Australia.
• Latin America and the Middle East & Africa are gradually strengthening migraine diagnosis and treatment through healthcare modernization, increased public awareness, improved neurological services, and greater availability of advanced therapeutic options.

Competitive and Strategic Outlook

• The growing epidemiological burden of migraine continues creating substantial opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, diagnostic technology developers, and digital health organizations. Industry participants are increasingly investing in improved screening programs, wearable monitoring technologies, artificial intelligence-assisted diagnostics, remote patient monitoring, and precision neurology to enhance disease detection and long-term patient management.
• Strategic collaboration among healthcare providers, academic institutions, pharmaceutical companies, digital health developers, and public health organizations continues strengthening epidemiological surveillance while improving patient outcomes. Future healthcare strategies are expected to emphasize early diagnosis, personalized treatment, digital patient engagement, and expanded access to specialized headache care.

Conclusion

• The global epidemiological burden of migraine is expected to remain substantial throughout the forecast period as population growth, aging, lifestyle changes, and increasing recognition of neurological disorders continue driving the number of affected individuals. With an estimated 1.2 billion people living with migraine worldwide, the disorder remains one of the leading causes of disability and healthcare burden globally. Continued improvements in disease awareness, diagnostic technologies, healthcare accessibility, and preventive treatment strategies are expected to strengthen patient identification and long-term management. Although underdiagnosis, unequal healthcare access, and variability in clinical presentation remain significant challenges, ongoing investment in neurological care and epidemiological research is expected to improve patient outcomes while supporting future healthcare planning.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global migraine prevalence, incidence, diagnosed patient population, demographic trends, and disease burden.
• Epidemiological Assessment: Analyze patient distribution by age, gender, disease subtype, diagnosis status, and geographic region.
• Market Drivers and Future Trends: Understand epidemiological developments, healthcare access improvements, and future patient population growth.
• Actionable Recommendations: Support healthcare planning, market forecasting, clinical development, and commercial strategy.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, research organizations, public health agencies, and policymakers.

What Businesses Use Our Reports For

• Epidemiology assessment, patient population forecasting, commercial opportunity evaluation, clinical trial planning, healthcare resource allocation, market entry strategy, investment analysis, public health planning, and competitive intelligence.

Report Coverage

• Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
• Epidemiological analysis by prevalence, incidence, diagnosed cases, disease subtype, age group, gender, and region
• Assessment of disease burden, diagnosis patterns, healthcare access, risk factors, and future epidemiological trends
• Analysis of unmet clinical needs, patient management, healthcare infrastructure, and emerging diagnostic technologies
• Regional analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
  • 1.1.1 Study Overview
  • 1.1.2 Epidemiology Coverage
  • 1.1.3 Forecast Framework (2025-2035)
• 1.2 Key Epidemiology Insights
  • 1.2.1 Global Disease Burden Snapshot
  • 1.2.2 Current Diagnosed Population
  • 1.2.3 Treated Population Assessment
  • 1.2.4 High-Growth Patient Segments
• 1.3 Key Forecast Highlights
  • 1.3.1 Incidence Forecast Summary
  • 1.3.2 Prevalence Forecast Summary
  • 1.3.3 Diagnosed Population Forecast
  • 1.3.4 Treatment-Seeking Population Forecast
• 1.4 Strategic Takeaways
  • 1.4.1 Major Epidemiological Trends
  • 1.4.2 Future Disease Burden Outlook
  • 1.4.3 Key Opportunities and Challenges

2. Disease Overview and Clinical Background

• 2.1 Migraine Disease Introduction
  • 2.1.1 Definition and Classification
  • 2.1.2 Disease Pathophysiology
  • 2.1.3 Burden of Disease
• 2.2 Migraine Subtypes
  • 2.2.1 Episodic Migraine
  • 2.2.2 Chronic Migraine
  • 2.2.3 Migraine with Aura
  • 2.2.4 Migraine without Aura
  • 2.2.5 Vestibular Migraine
  • 2.2.6 Hemiplegic Migraine
  • 2.2.7 Menstrual Migraine
• 2.3 Disease Progression and Natural History
  • 2.3.1 Disease Onset Patterns
  • 2.3.2 Progression from Episodic to Chronic Migraine
  • 2.3.3 Recurrence and Relapse Characteristics
• 2.4 Disease Burden Assessment
  • 2.4.1 Disability Burden
  • 2.4.2 Healthcare Resource Utilization
  • 2.4.3 Socioeconomic Impact
  • 2.4.4 Quality-of-Life Implications

3. Epidemiology Methodology and Forecast Framework

• 3.1 Epidemiology Model Design
  • 3.1.1 Population-Based Modeling Approach
  • 3.1.2 Data Triangulation Methodology
  • 3.1.3 Forecast Assumptions
• 3.2 Data Sources
  • 3.2.1 Published Epidemiological Literature
  • 3.2.2 Population Registries
  • 3.2.3 National Health Databases
  • 3.2.4 Government Statistics
  • 3.2.5 Expert Validation Framework
• 3.3 Forecasting Methodology
  • 3.3.1 Demographic Forecast Integration
  • 3.3.2 Age-Adjusted Projections
  • 3.3.3 Gender-Based Projections
  • 3.3.4 Urban-Rural Population Adjustments

4. Global Epidemiology Analysis

• 4.1 Global Incidence Analysis
  • 4.1.1 Historical Incidence Trends
  • 4.1.2 Annual Incident Cases (2020-2026)
  • 4.1.3 Incidence Growth Dynamics
• 4.2 Global Prevalence Analysis
  • 4.2.1 Historical Prevalence Trends
  • 4.2.2 Total Prevalent Cases (2020-2026)
  • 4.2.3 Prevalence Growth Drivers
• 4.3 Diagnosed Population Analysis
  • 4.3.1 Diagnosed Cases by Geography
  • 4.3.2 Diagnosis Gap Assessment
  • 4.3.3 Diagnostic Trends Forecast
• 4.4 Treatment-Seeking Population Analysis
  • 4.4.1 Healthcare Access Trends
  • 4.4.2 Physician Consultation Rates
  • 4.4.3 Treatment Uptake Trends

5. Epidemiology Segmentation Analysis

• 5.1 By Migraine Type
  • 5.1.1 Episodic Migraine
  • 5.1.2 Chronic Migraine
  • 5.1.3 Migraine with Aura
  • 5.1.4 Migraine without Aura
  • 5.1.5 Other Migraine Subtypes
• 5.2 By Age Group
  • 5.2.1 Pediatric Population
  • 5.2.2 Adolescents
  • 5.2.3 Young Adults
  • 5.2.4 Middle-Aged Adults
  • 5.2.5 Elderly Population
• 5.3 By Gender
  • 5.3.1 Female Population
  • 5.3.2 Male Population
  • 5.3.3 Gender-Specific Disease Trends
• 5.4 By Disease Severity
  • 5.4.1 Mild Migraine
  • 5.4.2 Moderate Migraine
  • 5.4.3 Severe Migraine
• 5.5 By Healthcare Setting
  • 5.5.1 Primary Care Diagnosis
  • 5.5.2 Neurology Specialist Diagnosis
  • 5.5.3 Hospital-Based Management

6. Epidemiological Risk Factor Analysis

• 6.1 Demographic Risk Factors
  • 6.1.1 Age-Related Risk
  • 6.1.2 Gender-Related Risk
  • 6.1.3 Genetic Predisposition
• 6.2 Lifestyle Risk Factors
  • 6.2.1 Sleep Disturbances
  • 6.2.2 Stress and Psychological Factors
  • 6.2.3 Dietary Triggers
  • 6.2.4 Physical Activity Patterns
• 6.3 Environmental Risk Factors
  • 6.3.1 Climate Influences
  • 6.3.2 Air Pollution Exposure
  • 6.3.3 Occupational Factors
• 6.4 Comorbidity Assessment
  • 6.4.1 Depression
  • 6.4.2 Anxiety Disorders
  • 6.4.3 Cardiovascular Conditions
  • 6.4.4 Sleep Disorders

7. Diagnosis and Patient Journey Analysis

• 7.1 Diagnostic Pathway Assessment
  • 7.1.1 Time to Diagnosis
  • 7.1.2 Referral Patterns
  • 7.1.3 Diagnostic Challenges
• 7.2 Patient Journey Mapping
  • 7.2.1 Symptom Recognition
  • 7.2.2 Healthcare Engagement
  • 7.2.3 Treatment Initiation
  • 7.2.4 Long-Term Disease Management
• 7.3 Disease Awareness Assessment
  • 7.3.1 Patient Awareness Levels
  • 7.3.2 Physician Awareness Trends
  • 7.3.3 Public Health Education Impact

8. Forecast Analysis (2026-2035)

• 8.1 Global Incidence Forecast
  • 8.1.1 Base Case Scenario
  • 8.1.2 Optimistic Scenario
  • 8.1.3 Conservative Scenario
• 8.2 Global Prevalence Forecast
  • 8.2.1 Total Population Forecast
  • 8.2.2 Growth Rate Assessment
  • 8.2.3 Long-Term Burden Projection
• 8.3 Diagnosed Population Forecast
  • 8.3.1 Diagnosis Rate Evolution
  • 8.3.2 Screening Impact Assessment
• 8.4 Treatment Population Forecast
  • 8.4.1 Treatment Uptake Trends
  • 8.4.2 Access-to-Care Improvements
  • 8.4.3 Healthcare Infrastructure Impact

9. Geographic Analysis

• 9.1 North America
  • 9.1.1 Incidence Analysis
  • 9.1.2 Prevalence Analysis
  • 9.1.3 Diagnosed Population
  • 9.1.4 Forecast Assessment
• 9.2 Europe
  • 9.2.1 Incidence Analysis
  • 9.2.2 Prevalence Analysis
  • 9.2.3 Diagnosed Population
  • 9.2.4 Forecast Assessment
• 9.3 Asia-Pacific
  • 9.3.1 Incidence Analysis
  • 9.3.2 Prevalence Analysis
  • 9.3.3 Diagnosed Population
  • 9.3.4 Forecast Assessment
• 9.4 Latin America
  • 9.4.1 Incidence Analysis
  • 9.4.2 Prevalence Analysis
  • 9.4.3 Diagnosed Population
  • 9.4.4 Forecast Assessment
• 9.5 Middle East & Africa
  • 9.5.1 Incidence Analysis
  • 9.5.2 Prevalence Analysis
  • 9.5.3 Diagnosed Population
  • 9.5.4 Forecast Assessment

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Incidence Trends
  • 10.1.2 Prevalence Trends
  • 10.1.3 Diagnosed Population
  • 10.1.4 Forecast Outlook
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Healthcare Access and Treatment Gap Analysis

• 11.1 Diagnosis Gap Assessment
  • 11.1.1 Undiagnosed Population
  • 11.1.2 Misdiagnosis Trends
• 11.2 Treatment Gap Assessment
  • 11.2.1 Untreated Population
  • 11.2.2 Access-to-Care Barriers
  • 11.2.3 Regional Variability
• 11.3 Healthcare Infrastructure Impact
  • 11.3.1 Neurologist Availability
  • 11.3.2 Specialty Care Access
  • 11.3.3 Digital Health Adoption

12. Future Epidemiology Outlook and Strategic Insights

• 12.1 Emerging Epidemiological Trends
  • 12.1.1 Demographic Shifts
  • 12.1.2 Urbanization Impact
  • 12.1.3 Lifestyle Evolution
• 12.2 Key Forecast Drivers
  • 12.2.1 Population Growth
  • 12.2.2 Aging Population Impact
  • 12.2.3 Healthcare Access Expansion
• 12.3 Strategic Insights
  • 12.3.1 High-Burden Markets
  • 12.3.2 High-Growth Patient Segments
  • 12.3.3 Future Disease Burden Hotspots

13. Appendix